Showing results (1281-1290 of 1,342) with videos related to

Sort By:
Pageof 135
Neuro-Oncology Advances|March 26, 2026
Gliomap-GAN: A conditional generative adversarial network to visualize glioblastoma's cell density from contrast-enhanced magnetic resonance imagingManabu Kinoshita, Keisuke Miyake, Wataru Ide, et al.
Neuro-Oncology Advances|April 1, 2026
Increased cortical excitability to transcranial magnetic stimulation at the brain-tumor interface of IDH1-mutant gliomasAlexia Stark, Mykola Gorbachuk, Kathrin Machetanz, et al.
Neuro-Oncology Advances|April 2, 2026
Utility of cerebrospinal fluid circulating tumor cell quantification and next-generation sequencing in patients with suspicion for leptomeningeal diseaseAmanda Onoichenco, Rosivel Galvez, Aaliyah Schultz, et al.
Neuro-Oncology Advances|April 22, 2024
Hippocampal subfield volumetric changes after radiotherapy for brain metastasesKlara Holikova, Iveta Selingerova, Petr Pospisil, et al.
Neuro-Oncology Advances|April 15, 2024
Single-nucleus expression characterization of non-enhancing region of recurrent high-grade gliomaKunal S Patel, Kaleab K Tessema, Riki Kawaguchi, et al.
Neuro-Oncology Advances|May 1, 2024
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphomaHajime Yonezawa, Yoshitaka Narita, Motoo Nagane, et al.
Neuro-Oncology Advances|April 10, 2024
Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group StudyRishi R Lulla, Allen Buxton, Mark D Krailo, et al.
Neuro-Oncology Advances|April 10, 2024
The outcomes measured and reported in observational studies of incidental and untreated intracranial meningioma: A systematic reviewChristopher P Millward, Abdurrahman I Islim, Terri S Armstrong, et al.
Neuro-Oncology Advances|April 4, 2024
Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in gliomaJordan J Jones, Hong Nguyen, Stephen Q Wong, et al.
Neuro-Oncology Advances|October 16, 2023
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastomaHao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, et al.
Pageof 135